Beruflich Dokumente
Kultur Dokumente
DOI 10.1007/s00415-004-1201-x
Hans-Peter Hartung
Huub Schellekens
Frederick E. Munschauer III
INTRODUCTION
JON 1201
II/2
Bertolotto, MD, Centro Riferimento Regionale Sclerosi Multipla, Orbassano, Italy; Nicole Casadevall, MD, Hopital Hotel Dieu, Paris,
France; Juha-Pekka Erlinna, MD, Finnish Special Neurology Center,
Turku, Finland; Professor Hans-Peter Hartung, Heinrich-Heine University, Dsseldorf, Germany; Professor Thibault Moreau, Hopital
General, Dijon, France; Professor Alfons Billiau, Rega Institute University of Leuven, Leuven, Belgium; Professor Florian Deisenhammer,
University of Innsbruck, Innsbruck, Austria; Paolo Gallo, MD, Clinica
Neurologica Prima, Padova, Italy; Professor Reinhard Hohlfeld, MaxPlanck-Institute for Neurobiology, Martinsried, Germany; Frederick
Munschauer, MD, The Jacobs Neurological Institute, Buffalo General
Hospital, Buffalo, New York, USA; Professor George Rice, Multiple
Sclerosis Clinic, London, Ontario, Canada; Pierrette Seeldrayers, MD,
CHU Charleroi, Charleroi, Belgium; Timothy Vartanian, MD, PhD,
Harvard Institute of Medicine, Boston, Mass., USA; Huub Schellekens,
MD, Utrecht University, Utrecht, The Netherlands; Professor Per
Slberg Srensen, Rigshospitalet, Copenhagen, Denmark.
References
1. Antonelli G, Giannelli G, Currenti M,
Simeoni E, Del Vecchio S, Maggi F,
Pistello M, Roffi L, Pastore G, Chemello
L, Dianzani F (1996) Antibodies to
interferon (IFN) in hepatitis C patients
relapsing while continuing recombinant IFN-2 therapy. Clin Exp
Immunol 104:384387
2. Bertolotto A, Malucchi S, Sala A,
Orefice G, Carrieri PB, Capobianco M,
Milano E, Melis F, Giordana MT (2002)
Differential effects of three interferon
betas on neutralising antibodies in patients with multiple sclerosis: a follow
up study in an independent laboratory.
J Neurol Neurosurg Psychiatry 73:
148153
3. Clanet M, Radue EW, Kappos L,
Hartung HP, Hohlfeld R, SandbergWollheim M, Kooijmans-Coutinho
MF, Tsao EC, Sandrick AW, and the
European IFN-1a (Avonex) DoseComparison Study Investigators
(2002) A randomized, double-blind,
dose-comparison study of weekly interferon -1a in relapsing MS. Neurology 59:15071517
4. European Study Group on Interferon
-1b in Secondary Progressive MS
(1998) Placebo-controlled multicentre
randomised trial of interferon -1b in
treatment of secondary progressive
multiple sclerosis. Lancet 352:
14911497
5. Freund M, von Wussow P, Diedrich H,
Eisert R, Link H, Wilke H, Buchholz F,
LeBlanc S, Fonatsch C, Deicher H, Poliwoda H (1989) Recombinant human
interferon (IFN) alpha-2 b in chronic
myelogenous leukemia: dose dependency of response and frequency of
neutralizing anti-interferon antibodies. Br J Haematol 72:350356
II/3